ALBO News and Press, Albireo Pharma Inc. From 04/06/22

Albireo Pharma Inc. (NASDAQ:ALBO) traded at a new 52-week high today of $52.81. So far today approximately 9.3 million shares have been exchanged, as compared to an average 30-day volume of 327,000 shares. Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on ...

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Albireo Pharma, Inc. (ALBO) Q4 2021 Earnings Conference Call March 1, 2022 10:00 AM ET Company Participants Paul Arndt – Managing Director-LifeSci Advisors, LLC Ron Cooper – President and Chief Executive Officer Pamela Stephenson – Chief Commercial Officer Simon Harford &...

The following slide deck was published by Albireo Pharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Albireo Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation

Albireo Pharma press release (NASDAQ:ALBO): Q4 GAAP EPS of -$0.57. Revenue of $32.52M (vs $2.72M in Q420). For further details see: Albireo Pharma GAAP EPS of -$0.57, revenue of $32.52M

Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 million NICE endorses clinical and economic benefits of Bylvay Phase 3 study in Alagille syndrome on track for readout in 2022 Reports $248.1 million of cash and cash eq...

Albireo Pharma (NASDAQ:ALBO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$1.81 and the consensus Revenue Estimate is $11.1M (+308.1% Y/Y). For further details see: Albireo Pharma Q4 2021 Earnings Preview

ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...

BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the hea...